Basic Information
RNALocate ID: | RLID:11003790 |
RNA Symbol: | hsa-miR-150-3p |
Localization: | Microvesicle |
RNA Information
RNA Name: | hsa-miR-150-star |
RNA ID: | miRBase:MIMAT0004610 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 23539611 |
Tissue/Cell Line: | Seminal plasma |
Method: | Microarray |
Description: | In order to assess the reversibility of post-vasectomy miRNA sequelae, we investigated whether SMV miRNAs altered by vasectomy could be retrieved in SMVs from normospermic vasovasostomized donors. miRNA microarray profiling performed on SMVs from normal, vasectomized and vasovasostomized donors identified 313 miRNAs whose intensity was above the threshold of detection. Among these miRNAs, 293 were detected in samples from normal donors, 275 in vasectomized donors and 298 in vasovasostomized donors (Fig. 3, Supplementary data, Table SIV). Data are collected from Table S4. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:11003787 | Exosome | Saliva | 19627513 |
RLID:11003788 | Exosome | Jurkat-derived T cell line (J77cl20) | 21505438 |
RLID:11003789 | Exosome | Plasma | 23663360 |
RLID-D:11000640 | Microvesicle | Colon cancer cell line (LIM1863)|Mesenchymal stem cells | |
RLID-D:11001515 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-150-3p | Medulloblastoma | MNDR-E-MI-16510 |
MNDR | hsa-miR-150-3p | B cell lymphoma of malt type | MNDR-E-MI-16511 |
MNDR | hsa-miR-150-3p | Lymphoma | MNDR-E-MI-16512 |
MNDR | hsa-miR-150-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-16513 |
MNDR | hsa-miR-150-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-16514 |
MNDR | hsa-miR-150-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-16515 |
MNDR | hsa-miR-150-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-16516 |
MNDR | hsa-miR-150-3p | Her2-receptor positive breast cancer | MNDR-E-MI-16517 |
MNDR | hsa-miR-150-3p | Breast cancer luminal | MNDR-E-MI-16518 |
MNDR | hsa-miR-150-3p | Prostate cancer | MNDR-E-MI-16519 |
MNDR | hsa-miR-150-3p | Gastric cancer | MNDR-E-MI-16520 |
MNDR | hsa-miR-150-3p | Intracranial aneurysm | MNDR-E-MI-16521 |
MNDR | hsa-miR-150-3p | Lung cancer | MNDR-E-MI-16522 |
MNDR | hsa-miR-150-3p | Biliary atresia | MNDR-E-MI-16523 |
MNDR | hsa-miR-150-3p | Parkinson disease | MNDR-E-MI-16524 |
MNDR | hsa-miR-150-3p | Basal-like breast cancer | MNDR-E-MI-16525 |
MNDR | hsa-miR-150-3p | Pancreatic cancer | MNDR-E-MI-16526 |
MNDR | hsa-miR-150-3p | Rectum adenocarcinoma | MNDR-E-MI-16527 |
MNDR | hsa-miR-150-3p | Nephroblastoma | MNDR-E-MI-16528 |
MNDR | hsa-miR-150-3p | Colon cancer | MNDR-E-MI-16529 |
MNDR | hsa-miR-150-3p | Colon adenocarcinoma | MNDR-E-MI-16530 |
MNDR | hsa-miR-150-3p | Familial ovarian cancer | MNDR-E-MI-16531 |
MNDR | hsa-miR-150-3p | Carcinoma ductal breast | MNDR-E-MI-16532 |
MNDR | hsa-miR-150-3p | Glioblastoma | MNDR-E-MI-16533 |
MNDR | hsa-miR-150-3p | Astrocytoma | MNDR-E-MI-16534 |
MNDR | hsa-miR-150-3p | Chordoma | MNDR-E-MI-16535 |
MNDR | hsa-miR-150-3p | Osteosarcoma | MNDR-E-MI-16536 |
MNDR | hsa-miR-150-3p | Infarction middle cerebral artery | MNDR-E-MI-16537 |
MNDR | hsa-miR-150-3p | Liver cancer | MNDR-E-MI-16538 |
MNDR | hsa-miR-150-3p | Gastric adenocarcinoma | MNDR-E-MI-16539 |
MNDR | hsa-miR-150-3p | Lung squamous cell carcinoma | MNDR-E-MI-16540 |
MNDR | hsa-miR-150-3p | Lung adenocarcinoma | MNDR-E-MI-16541 |
MNDR | hsa-miR-150-3p | Thyroid carcinoma | MNDR-E-MI-16542 |
MNDR | hsa-miR-150-3p | Bladder urothelial carcinoma | MNDR-E-MI-16543 |
MNDR | hsa-miR-150-3p | Pancreatic adenocarcinoma | MNDR-E-MI-16544 |
MNDR | hsa-miR-150-3p | Kidney renal clear cell carcinoma | MNDR-E-MI-16545 |
MNDR | hsa-miR-150-3p | Renal clear cell carcinoma | MNDR-E-MI-16546 |
MNDR | hsa-miR-150-3p | Biliary tract cancer | MNDR-E-MI-16547 |
MNDR | hsa-miR-150-3p | Cholangiocarcinoma | MNDR-E-MI-16548 |
MNDR | hsa-miR-150-3p | Esophageal cancer | MNDR-E-MI-16549 |
MNDR | hsa-miR-150-3p | Lung small cell carcinoma | MNDR-E-MI-16550 |
MNDR | hsa-miR-150-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-16551 |
MNDR | hsa-miR-150-3p | Testicular germ cell cancer | MNDR-E-MI-16552 |
MNDR | hsa-miR-150-3p | Myocardial infarction | MNDR-E-MI-16553 |
MNDR | hsa-miR-150-3p | Breast invasive carcinoma | MNDR-E-MI-16554 |
MNDR | hsa-miR-150-3p | Hepatocellular carcinoma | MNDR-E-MI-16555 |
MNDR | hsa-miR-150-3p | Embryonal cancer | MNDR-E-MI-16556 |
MNDR | hsa-miR-150-3p | Familiar ovarian carcinoma | MNDR-E-MI-16557 |
MNDR | hsa-miR-150-3p | B-cell lymphoma | MNDR-E-MI-16558 |
MNDR | hsa-miR-150-3p | Hodgkin lymphoma | MNDR-E-MI-16559 |
MNDR | hsa-miR-150-3p | Skin cutaneous melanoma | MNDR-E-MI-16560 |
MNDR | hsa-miR-150-3p | Skin melanoma | MNDR-E-MI-16561 |
MNDR | hsa-miR-150-3p | Colorectal cancer | MNDR-E-MI-16562 |
MNDR | hsa-miR-150-3p | Nasopharynx carcinoma | MNDR-E-MI-16563 |
MNDR | hsa-miR-150-3p | Multiple myeloma | MNDR-E-MI-16564 |
MNDR | hsa-miR-150-3p | Esophageal squamous cell carcinoma | MNDR-E-MI-16565 |
MNDR | hsa-miR-150-3p | Nasopharyngeal cancer | MNDR-E-MI-16566 |
MNDR | hsa-miR-150-3p | Intracranial hemorrhage hypertensive | MNDR-E-MI-16567 |
MNDR | hsa-miR-150-3p | Breast cancer her3+ negative | MNDR-E-MI-16568 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | CCNT1 | Homo sapiens | RR00296614 |
TOP